Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Assess the Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature

NCT05288127 is registered in ClinicalTrials.gov with University of Malaya as lead sponsor.

NCT NCT05288127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05288127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Assess the Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature
Lead sponsor
University of Malaya
Phase
Phase 2
Overall status
Unknown status
Start date
March 8, 2022
Completion date
November 30, 2025
Enrollment
55 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hrd 100 gene expression high, triple negative breast cancer